Bank of New York Mellon’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-584,347
| Closed | -$11.8M | – | 4373 |
|
|
2026
Q1 | $11.8M | Sell |
584,347
-110,828
| -16% | -$1.79M | ﹤0.01% | 1848 |
|
|
2025
Q4 | $11.2M | Buy |
695,175
+98,701
| +17% | +$1.31M | ﹤0.01% | 1863 |
|
|
2025
Q3 | $7.27M | Buy |
596,474
+488,839
| +454% | +$6.75M | ﹤0.01% | 2112 |
|
|
2025
Q2 | $1.22M | Buy |
107,635
+4,105
| +4% | +$50.2K | ﹤0.01% | 3023 |
|
|
2025
Q1 | $1.19M | Buy |
103,530
+4,983
| +5% | +$50.9K | ﹤0.01% | 2959 |
|
|
2024
Q4 | $835K | Sell |
98,547
-7,064
| -7% | -$73.2K | ﹤0.01% | 3262 |
|
|
2024
Q3 | $1.22M | Sell |
105,611
-29,989
| -22% | -$377K | ﹤0.01% | 3020 |
|
|
2024
Q2 | $1.6M | Buy |
135,600
+23,547
| +21% | +$275K | ﹤0.01% | 2921 |
|
|
2024
Q1 | $1.33M | Buy |
112,053
+11,360
| +11% | +$151K | ﹤0.01% | 2997 |
|
|
2023
Q4 | $1.23M | Buy |
100,693
+16,384
| +19% | +$149K | ﹤0.01% | 3084 |
|
|
2023
Q3 | $812K | Buy |
84,309
+1,508
| +2% | +$15.4K | ﹤0.01% | 3285 |
|
|
2023
Q2 | $745K | Sell |
82,801
-210
| -0.3% | -$1.94K | ﹤0.01% | 3382 |
|
|
2023
Q1 | $652K | Sell |
83,011
-7
| -0% | -$52 | ﹤0.01% | 3351 |
|
|
2022
Q4 | $561K | Buy |
83,018
+286
| +0.3% | +$1.53K | ﹤0.01% | 3484 |
|
|
2022
Q3 | $1.2M | Buy |
82,732
+9,597
| +13% | +$134K | ﹤0.01% | 3114 |
|
|
2022
Q2 | $719K | Buy |
73,135
+3,565
| +5% | +$39.3K | ﹤0.01% | 3368 |
|
|
2022
Q1 | $1.03M | Buy |
69,570
+3,838
| +6% | +$55.1K | ﹤0.01% | 3300 |
|
|
2021
Q4 | $870K | Sell |
65,732
-7,504
| -10% | -$119K | ﹤0.01% | 3466 |
|
|
2021
Q3 | $1.28M | Sell |
73,236
-12,444
| -15% | -$252K | ﹤0.01% | 3253 |
|
|
2021
Q2 | $2.05M | Sell |
85,680
-24,824
| -22% | -$649K | ﹤0.01% | 2966 |
|
|
2021
Q1 | $2.84M | Buy |
110,504
+65,175
| +144% | +$1.71M | ﹤0.01% | 2721 |
|
|
2020
Q4 | $861K | Buy |
45,329
+3,250
| +8% | +$55.7K | ﹤0.01% | 3338 |
|
|
2020
Q3 | $529K | Sell |
42,079
-101
| -0.2% | -$1.26K | ﹤0.01% | 3461 |
|
|
2020
Q2 | $511K | Buy |
42,180
+7,111
| +20% | +$75.6K | ﹤0.01% | 3457 |
|
|
2020
Q1 | $268K | Buy |
35,069
+70
| +0.2% | +$944 | ﹤0.01% | 3650 |
|
|
2019
Q4 | $623K | Sell |
34,999
-1,900
| -5% | -$24.8K | ﹤0.01% | 3475 |
|
|
2019
Q3 | $428K | Sell |
36,899
-2,187
| -6% | -$35.3K | ﹤0.01% | 3620 |
|
|
2019
Q2 | $865K | Buy |
39,086
+31,958
| +448% | +$749K | ﹤0.01% | 3312 |
|
|
2019
Q1 | $204K | Buy |
+7,128
| New | +$155K | ﹤0.01% | 3881 |
|
|
2016
Q4 | – | Sell |
-1,018
| Closed | -$7K | – | 4291 |
|
|
2016
Q3 | $7K | Sell |
1,018
-91
| -8% | -$686 | ﹤0.01% | 4255 |
|
|
2016
Q2 | $10K | Sell |
1,109
-1,681
| -60% | -$19.5K | ﹤0.01% | 4291 |
|
|
2016
Q1 | $25K | Hold |
2,790
| – | – | ﹤0.01% | 4159 |
|
|
2015
Q4 | $141K | Buy |
2,790
+120
| +4% | +$6.28K | ﹤0.01% | 3975 |
|
|
2015
Q3 | $133K | Sell |
2,670
-639
| -19% | -$54.5K | ﹤0.01% | 4033 |
|
|
2015
Q2 | $331K | Buy |
+3,309
| New | +$328K | ﹤0.01% | 3757 |
|
Other funds holding KALV
Bank of New York Mellon's KALV Position: Q2 2026 in Review
Bank of New York Mellon sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 584,347 shares — an estimated $11.8M sold.
Bank of New York Mellon first reported a position in KALV in Q2 2015 and held it in 35 quarters. The position peaked at $11.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Bank of New York Mellon reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Bank of New York Mellon sold 584,347 KalVista Pharmaceuticals shares in Q2 2026, an estimated $11.8M.
- Bank of New York Mellon first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 35 quarters.
- Bank of New York Mellon's KalVista Pharmaceuticals position peaked at $11.8M in Q1 2026.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.